Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections. The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine whether treating people who test positive for coronavirus but who do not have symptoms or have mild symptoms with this combination will reduce the amount of virus and their chances of getting sick. To read the full story.
Home / News / Researchers are investigating a potential treatment for people recently diagnosed with SARS-CoV-2 who have no or mild symptoms
Recent Posts
- NJ ACTS Special Populations Virtual Seminar on 9/24 at 12pm – Register Now
- NJ ACTS CREST (R25) Funded
- NJ ACTS Workforce Development Internship Fall 2024 – Deadline Today
- Rutgers Health Researchers Find Disparities in Outcomes of Hospice Discharges.
- NJIT Researchers Close in on New Technology for Objectively Measuring Pain.
Categories
- Community (1,990)
- Covid (974)
- CTO Events (1)
- News (2,536)
- Pilots (20)